3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Opportunistic Infections
1
Inflammation
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Metformin
3
Letrozole
3
Sperm Injections, Intracytoplasmic
2
Progesterone
2
Lidocaine
2
Indocyanine Green
2
Gentamicins
2
Estradiol
2
Clomiphene
2
Bevacizumab
2
Acitretin
2
tirbanibulin
1
technetium Tc 99m nanocolloid
1
suvorexant
1
pomalidomide
1
pembrolizumab
1
pasireotide
1
nilotinib
1
methylnaltrexone
1
ledipasvir
1
ixazomib
1
gadolinium ethoxybenzyl DTPA
1
gadofosveset trisodium
1
exemestane
1
encorafenib
1
dolutegravir
1
ceftolozane, tazobactam drug combination
1
binimetinib
1
bicalutamide
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Withdrawn
×
dolutegravir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn